Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, 127 West Changle Road, Xi'an, 710032, Shaanxi, China.
Cadre' s sanitarium, 62101 Army of PLA, 67 Nahu Road, Xinyang, 464000, Henan, China.
BMC Cancer. 2020 Feb 24;20(1):149. doi: 10.1186/s12885-020-6619-8.
It remains controversial whether prophylactic No.10 lymph node clearance is necessary for gastric cancer. Thus, the present study aims to investigate the impact of prophylactic No.10 lymph node clearance on the perioperative complications and prognosis of upper and middle third gastric cancer.
A network meta-analysis to identify both direct and indirect evidence with respect to the comparison of gastrectomy alone (G-A), gastrectomy combination with splenectomy (G + S) and gastrectomy combination with spleen-preserving splenic hilar dissection (G + SPSHD) was conducted. We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for studies published before September 2018. Perioperative complications and overall survival were analyzed. Hazard ratios (HR) were extracted from the publications on the basis of reported values or were extracted from survival curves by established methods.
Ten retrospective studies involving 2565 patients were included. In the direct comparison analyses, G-A showed comparable 5-year overall survival rate (HR: 1.1, 95%CI: 0.97-1.3) but lower total complication rate (OR: 0.37, 95%CI: 0.17-0.77) compared with G + S. Similarly, the 5-year overall survival rate between G + SPSHD and G + S was comparable (HR: 1.1, 95%CI: 0.92-1.4), while the total complication rate of G + SPSHD was lower than that of G + S (OR: 0.50, 95%CI: 0.28-0.88). In the indirect comparison analyses, both the 5-year overall survival rate (HR: 1.0, 95%CI: 0.78-1.3) and total complication rate (OR: 0.75, 95%CI: 0.29-1.9) were comparable between G-A and G + SPSHD.
Prophylactic No.10 lymph node clearance was not recommended for treatment of upper and middle third gastric cancer.
预防性清扫第 10 组淋巴结是否对胃癌有必要仍然存在争议。因此,本研究旨在探讨预防性清扫第 10 组淋巴结对上、中段胃癌围手术期并发症和预后的影响。
通过网络荟萃分析,对胃切除术(G-A)、胃切除术联合脾切除术(G+S)和胃切除术联合保留脾脏脾门解剖术(G+SPSHD)的直接和间接证据进行比较。我们检索了 Medline、Embase 和 Cochrane 中心对照试验注册库(CENTRAL),检索截至 2018 年 9 月前发表的研究。分析围手术期并发症和总生存率。根据报道值从文献中提取风险比(HR),或通过已建立的方法从生存曲线中提取。
纳入了 10 项回顾性研究,共 2565 例患者。在直接比较分析中,G-A 组的 5 年总生存率(HR:1.1,95%CI:0.97-1.3)相似,但总并发症发生率(OR:0.37,95%CI:0.17-0.77)较低。同样,G+SPSHD 与 G+S 之间的 5 年总生存率(HR:1.1,95%CI:0.92-1.4)相似,而 G+SPSHD 的总并发症发生率低于 G+S(OR:0.50,95%CI:0.28-0.88)。在间接比较分析中,G-A 和 G+SPSHD 组的 5 年总生存率(HR:1.0,95%CI:0.78-1.3)和总并发症发生率(OR:0.75,95%CI:0.29-1.9)相似。
不建议预防性清扫第 10 组淋巴结治疗上、中段胃癌。